Cartesian Therapeutics Inc (RNAC)

Currency in USD
12.330
-0.480(-3.75%)
Closed·
After Hours
12.3300.000(0.00%)
·
RNAC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RNAC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.06013.100
52 wk Range
8.46026.500
Key Statistics
Prev. Close
12.33
Open
12.56
Day's Range
12.06-13.1
52 wk Range
8.46-26.5
Volume
77.86K
Average Volume (3m)
73.94K
1-Year Change
-14.37%
Book Value / Share
-0.84
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RNAC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
36.429
Upside
+195.45%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Cartesian Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Cartesian Therapeutics Inc Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

Compare RNAC to Peers and Sector

Metrics to compare
RNAC
Peers
Sector
Relationship
P/E Ratio
−8.4x−1.5x−0.5x
PEG Ratio
−0.09−0.020.00
Price/Book
−14.7x0.8x2.6x
Price / LTM Sales
9.4x4.8x3.3x
Upside (Analyst Target)
224.4%417.0%45.1%
Fair Value Upside
Unlock40.3%7.4%Unlock

Analyst Ratings

7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 36.429
(+195.45% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.68 / -0.67
Revenue / Forecast
1.10M / --
EPS Revisions
Last 90 days

RNAC Income Statement

People Also Watch

260.07
AVAV
-2.83%
168.10
CRCL
-8.40%
37.26
EXEL
+2.87%
208.33
LEU
-3.28%
2.100
VOR
+1.45%

FAQ

What Stock Exchange Does Cartesian Therapeutics Trade On?

Cartesian Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cartesian Therapeutics?

The stock symbol for Cartesian Therapeutics is "RNAC."

What Is the Cartesian Therapeutics Market Cap?

As of today, Cartesian Therapeutics market cap is 320.02M.

What Is Cartesian Therapeutics's Earnings Per Share (TTM)?

The Cartesian Therapeutics EPS (TTM) is -1.71.

From a Technical Analysis Perspective, Is RNAC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cartesian Therapeutics Stock Split?

Cartesian Therapeutics has split 1 times.

How Many Employees Does Cartesian Therapeutics Have?

Cartesian Therapeutics has 66 employees.

What is the current trading status of Cartesian Therapeutics (RNAC)?

As of 04 Aug 2025, Cartesian Therapeutics (RNAC) is trading at a price of 12.33, with a previous close of 12.33. The stock has fluctuated within a day range of 12.06 to 13.10, while its 52-week range spans from 8.46 to 26.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.